Effect of Vibrating Mesh Nebulizer Aerosol Technology on the In Vitro Activity of Ribavirin Against Respiratory Syncytial Virus
Open Access
- 27 September 2021
- journal article
- research article
- Published by SAGE Publications in Respiratory Care
- Vol. 67 (4) , 421-427
Abstract
BACKGROUND: Ribavirin is an antiviral drug that for many years has been administered to the lungs by aerosolization. Despite advancements in oral delivery routes, there has been a renewed interested in delivering ribavirin via the pulmonary system in select patients and the severely ill. The vibrating mesh nebulizer was previously demonstrated to be an effective alternative to the small-particle aerosol generator in particle size, chemical makeup, and concentrations of the ribavirin before and after nebulization. However, the antiviral activity of ribavirin has never been examined. We sought to study ribavirin’s activity before and after nebulization via vibrating mesh nebulizer. METHODS: We grew and infected human epithelial type 2 cells and primary airway epithelial cells with respiratory syncytial virus (RSV). We then compared the antiviral effect of non-nebulized (control) and aerosolized ribavirin to untreated controls. We used traditional plaque assay and real-time polymerase chain reaction to determine the quantity of virus. RESULTS: Both non-nebulized (control) and nebulized ribavirin reduced the size of RSV plaques compared to untreated controls. Additionally, the non-nebulized and nebulized ribavirin equally inhibited RSV replication. There were no statistically significant differences between the non-nebulized and nebulized ribavirin across all time points. CONCLUSIONS: The vibrating mesh nebulizer did not affect the antiviral properties of nebulized ribavirin when compared to non-nebulized drug. Our findings add supporting evidence for the use of the vibrating mesh nebulizer in the administration of inhaled ribavirin.Keywords
This publication has 32 references indexed in Scilit:
- Influences of Cannula Size and Flow Rate on Aerosol Drug Delivery Through the Vapotherm Humidified High-Flow Nasal Cannula SystemPediatric Critical Care Medicine, 2013
- Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and CoronavirusClinical Infectious Diseases, 2012
- An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus InfectionThe Journal of Infectious Diseases, 2012
- In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannulaPediatric Pulmonology, 2011
- Management of RSV infections in adult recipients of hematopoietic stem cell transplantationBlood, 2011
- Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cellsVirology Journal, 2011
- Performance of the Vibrating Membrane Aerosol Generation Device: Aeroneb Micropump Nebulizer ™Journal of Aerosol Medicine, 2007
- Selection of reliable reference genes for qPCR studies on chondroprotective actionBMC Molecular Biology, 2007
- Mechanisms of action of ribavirin against distinct virusesReviews in Medical Virology, 2005
- Phosphorylation of Ribavirin and Viramidine by Adenosine Kinase and Cytosolic 5′-Nucleotidase II: Implications for Ribavirin Metabolism in ErythrocytesAntimicrobial Agents and Chemotherapy, 2005